Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

"Patient safety remains a top priority for Novo Nordisk and the extensive nationwide legal actions we have taken to protect ...

Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...

70. Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug semaglutide, sold under the brand names Ozempic and Wegovy.

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.